Vaccines for prevention of group B meningococcal disease: Not your father's vaccines

Vaccine

Volumn 33, Issue , 2015, Pages D32-D38

  Harrison, Lee H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Factor H binding protein; Meningococcal; Meningococcal group B vaccines; Meningococcal vaccines; Meningococcus; Neisseria heparin binding antigen; Neisseria meningitidis; Neisserial adhesin A; Oropharyngeal carriage; Outer membrane vesicles

Indexed keywords

MENINGOCOCCUS VACCINE; ADHESIN; BACTERIAL ANTIGEN; OUTER MEMBRANE PROTEIN;

BACTERIAL STRAIN; DRUG COST; DRUG EFFICACY; HUMAN; IMMUNIZATION; MENINGOCOCCOSIS; PRIORITY JOURNAL; REVIEW; VACCINATION; ADOLESCENT; ANTIGENIC VARIATION; ECONOMICS; IMMUNOLOGY; INFANT; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; NEISSERIA MENINGITIDIS; OROPHARYNX; UNITED STATES;

ADHESINS, BACTERIAL; ADOLESCENT; ANTIGENIC VARIATION; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; OROPHARYNX; UNITED STATES;

EID: 84951567161     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.101     Document Type: Review

References (93)

1. McNeil L.K., Zagursky R.J., Lin S.L., Murphy E., Zlotnick G.W., Hoiseth S.K., et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev 2013, 77:234-252. PMCID: 3668674.
2. Andrews S.M., Pollard A.J. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet Infect Dis 2014, 14:426-434.
3. Rollier C.S., Dold C., Marsay L., Sadarangani M., Pollard A.J. The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy. Expert Opin Biol Ther 2015, 15:131-142.
4. Viner R.M., Booy R., Johnson H., Edmunds W.J., Hudson L., Bedford H., et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012, 11:774-783.
5. Kaplan S.L., Schutze G.E., Leake J.A., Barson W.J., Halasa N.B., Byington C.L., et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006, 118:e979-e984.
6. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50:184-191.
7. MacNeil J. Epidemiology of serogroup B meningococcal disease, United States. Presentation to the Advisory Committee on Immunization Practices 2014, October.
8. Trotter C.L., Greenwood B.M. Meningococcal carriage in the African meningitis belt. Lancet Infect Dis 2007, 7:797-803.
9. Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:853-861.
10. MacLennan J., Kafatos G., Neal K., Andrews N., Cameron J.C., Roberts R., et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006, 12:950-957.
11. Harrison L.H., Shutt K.A., Arnold K.E., Stern E.J., Pondo T., Kiehlbauch J.A., et al. Meningococcal carriage among georgia and Maryland high school students. J Infect Dis 2015, 211:1761-1768.
12. Kellerman S.E., McCombs K., Ray M., Baughman W., Reeves M.W., Popovic T., et al. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis 2002, 186:40-48.
13. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54:1-21.
14. Ladhani S.N., Beebeejaun K., Lucidarme J., Campbell H., Gray S., Kaczmarski E., et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis 2015, 60:578-585.
15. MacNeil J.R., Bennett N., Farley M.M., Harrison L.H., Lynfield R., Nichols M., et al. Epidemiology of infant meningococcal disease in the United States, 2006-2012. Pediatrics 2015, 135:e305-e311.
16. Harrison L.H., Dwyer D.M., Maples C.T., Billmann L. Risk of meningococcal infection in college students. JAMA 1999, 281:1906-1910.
17. Bruce M.G., Rosenstein N.E., Capparella J.M., Shutt K.A., Perkins B.A., Collins M. Risk factors for meningococcal disease in college students. JAMA 2001, 286:688-693.
18. Centers for Disease Control and Prevention Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49:13-20.
19. Brooks R., Woods C.W., Benjamin D.K., Rosenstein N.E. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 2006, 43:49-54.
20. Meyer S. Epidemiology of meningococcal disease outbreaks in the United States. Presentation to the Advisory Committee on Immunization Practices 2014, Available from www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-06/Meningococcal-02-Meyer.pdf (accessed June 6).
21. Ladhani S.N., Flood J.S., Ramsay M.E., Campbell H., Gray S.J., Kaczmarski E.B., et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 2012, 30:3710-3716.
22. Lahra M.M., Enriquez R.P. Australian Meningococcal Surveillance Programme annual report, 2012. Commun Dis Intell Q Rep 2013, 37:E224-E232.
23. Harrison L.H. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006, 19:142-164.
24. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
25. Halperin S.A., Bettinger J.A., Greenwood B., Harrison L.H., Jelfs J., Ladhani S.N., et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012, 30(Suppl. 2):B26-B36.
26. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
27. Sadarangani M., Scheifele D.W., Halperin S.A., Vaudry W., Le Saux N., Tsang R., et al. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. Clin Infect Dis 2014, 59:1208-1215.
28. Tauil Mde C., Carvalho C.S., Vieira A.C., Waldman E.A. Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil. Braz J Infect Dis 2014, 18:379-386.
29. Campbell H., Andrews N., Borrow R., Trotter C., Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17:840-847. PMCID: 2863391.
30. Novak R.T., Kambou J.L., Diomande F.V., Tarbangdo T.F., Ouedraogo-Traore R., Sangare L., et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12:757-764.
31. Daugla D.M., Gami J.P., Gamougam K., Naibei N., Mbainadji L., Narbe M., et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014, 383:40-47. PMCID: 3898950.
32. Gamougam K., Daugla D.M., Toralta J., Ngadoua C., Fermon F., Page A.L., et al. Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013. Emerg Infect Dis 2015, 21:115-118.
33. Bijlsma M.W., Brouwer M.C., Spanjaard L., van de Beek D., van der Ende A. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Clin Infect Dis 2014, 59:1216-1221.
34. Maiden M.C., Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359:1829-1830.
35. Maiden M.C., Ibarz-Pavon A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743.
36. Kristiansen P.A., Diomande F., Ba A.K., Sanou I., Ouedraogo A.S., Ouedraogo R., et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013, 56:354-363.
37. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br Med J 2003, 326:365-366.
38. Kelly C., Arnold R., Galloway Y., O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166:817-823.
39. Granoff D.M., Pelton S., Harrison L.H. Meningococcal vaccines. Vaccines 2013, 388-418. Saunders Elsevier, Philadelphia. 6th ed. S. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
40. Sacchi C.T., Whitney A.M., Popovic T., Beall D.S., Reeves M.W., Plikaytis B.D., et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000, 182:1169-1176.
41. Harrison L.H., Shutt K.A., Schmink S.E., Marsh J.W., Harcourt B.H., Wang X., et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005. J Infect Dis 2010, 201:1208-1224. PMCID: 2838939.
42. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
43. Seib K.L., Zhao X., Rappuoli R. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin Microbiol Infect 2012, 18(Suppl. 5):109-116.
44. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZBtrade mark: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
45. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
46. Pajon R., Beernink P.T., Harrison L.H., Granoff D.M. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28:2122-2129. PMCID: 2830318.
47. Wang X., Cohn A., Comanducci M., Andrew L., Zhao X., MacNeil J.R., et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011, 29:4739-4744.
48. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582.
49. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28:6086-6093.
50. Gilca R., Deceuninck G., Lefebvre B., Tsang R., Amini R., Gilca V., et al. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS ONE 2012, 7:e50659. PMCID: 3510192.
51. Agence de la Santé et des Services Sociaux du Saguenay - Lac-Saint-Jean Québec. Première vague de vaccination contre le méningocoque de sérogroupe B. Available from (accessed 19.06.14). http://www.csrsaguenay.qc.ca/medias/csrsaguenay/fichiers/Actualite/Communique_fin_campagne_printemps_140618_3.pdf.
52. Agence de la Santé et des Services Sociaux du Saguenay - Lac-Saint-Jean Québec. Targeted Meningococcal Serogroup B Vaccination Campaign in the Saguenay - Lac-Saint-Jean Region. , 2014. http://www.msss.gouv.qc.ca/sujets/santepub/vaccination/index.php?meningococcal-b-vaccination-campaign.
53. McNamara L.A., Shumate A.M., Johnsen P., MacNeil J.R., Patel M., Bhavsar T., et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics 2015, 135:798-804.
54. Soeters H.M., McNamara L.A., Whaley M., Wang X., Alexander-Scott N., Kanadanian K.V., et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college - Rhode Island, 2015. MMWR Morb Mortal Wkly Rep 2015, 64:606-607.
55. Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK, March 2014. Available from (accessed 21.03.14). http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JCVI_Statement_on_MenB.pdf.
56. Folaranmi T., Rubin L., Martin S.W., Patel M., MacNeil J.R. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015, 64:608-612.
57. Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013, 62:52-54.
58. MacNeil J.R., Rubin L., McNamara L., Briere E.C., Clark T.A., Cohn A.C. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep 2014, 63:527-530.
59. Novartis. Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents. Available from (accessed 19.01.15). https://clinicaltrials.gov/ct2/show/NCT02212457.
60. Block S.L., Szenborn L., Daly W., Jackowska T., D'Agostino D., Han L., et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine 2015, (March). pii:S0264-410X(15)00274-1 [Epub ahead of print]. 10.1016/j.vaccine.2015.03.001.
61. Martinon-Torres F., Gimenez-Sanchez F., Bernaola-Iturbe E., Diez-Domingo J., Jiang Q., Perez J.L. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine 2014, 32:5206-5211.
62. Santolaya M.E., O'Ryan M., Valenzuela M.T., Prado V., Vergara R.F., Munoz A., et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 2013, 9:2304-2310. PMCID: 3981837.
63. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
64. McIntosh E.D., Carey V., Toneatto D., Dull P., Wassil J. Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection. Ther Adv Vaccines 2015, 3:13-23.
65. McQuaid F., Snape M.D., John T.M., Kelly S., Robinson H., Houlden J., et al. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J 2014, 33:760-766.
66. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13:416-425.
67. Kim E., Paulos S., Carlone G., Plikaytis B., Cohn A., Messonnier N., et al. Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States. International Pathogenic Neisseria Conference 2012.
68. Marshall H.S., Richmond P.C., Nissen M.D., Wouters A., Baber J., Jiang Q., et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013, 31:1569-1575.
69. Nissen M.D., Marshall H.S., Richmond P.C., Jiang Q., Harris S.L., Jones T.R., et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013, 32:364-371.
70. Read R.C., Baxter D., Chadwick D.R., Faust S.N., Finn A., Gordon S.B., et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014, 384:2123-2131.
71. Stephens D.S. Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics. Trans Am Clin Climatol Assoc 2011, 122:115-123. PMCID: 3116338.
72. Harrison L.H., Jolley K.A., Shutt K.A., Marsh J.W., O'Leary M., Sanza L.T., et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006, 193:1266-1274.
73. Wang X., Shutt K.A., Vuong J.T., Cohn A., MacNeil J., Schmink S., et al. Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure. J Infect Dis 2015, (January). pii: jiu842 [Epub ahead of print].
74. Moore M.R., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197:1016-1027.
75. Pawloski L.C., Queenan A.M., Cassiday P.K., Lynch A.S., Harrison M.J., Shang W., et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol 2014, 21:119-125. PMCID: 3910938.
76. Martin S.W., Pawloski L., Williams M., Weening K., DeBolt C., Qin X., et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis 2015, 60:223-227.
77. Lucidarme J., Tan L., Exley R.M., Findlow J., Borrow R., Tang C.M. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 2011, 18:1002-1014. PMCID: 3122619.
78. Giuntini S., Vu D.M., Granoff D.M. fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations. Vaccine 2013, 31:4192-4199. PMCID: 3756549.
79. Lewis L.A., Vu D.M., Granoff D.M., Ram S. Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model. Infect Immun 2014, 82:2574-2584. PMCID: 4019150.
80. Castiñeiras T.M.P.P., Barroso D.E., Marsh J.W., Krauland M.G., Schlackman J.L., Shutt K.A., et al. Diversity of noncapsular antigens among Neisseria meningitidis isolates of serogroups C, W135 and Y in Brazil: implications for vaccine prevention. International Pathogenic Neisseria Conference 2012.
81. Marsh J.W., O'Leary M.M., Shutt K.A., Harrison L.H. Deletion of fetA gene sequences in serogroup B and C Neisseria meningitidis isolates. J Clin Microbiol 2007, 45:1333-1335.
82. Perez-Trallero E., Esnal O., Marimon J.M. Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero(R)) in Gipuzkoa, Northern Spain. PLOS ONE 2014, 9:e116024.
83. National vaccination coverage among adolescents aged 13-17 years - United States, 2006. MMWR Morb Mortal Wkly Rep 2007, 56:885-888.
84. Elam-Evans L.D., Yankey D., Jeyarajah J., Singleton J.A., Curtis R.C., MacNeil J., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2013. MMWR Morb Mortal Wkly Rep 2014, 63:625-633.
85. Rosenthal E. The price of prevention: vaccine costs are soaring. The New York Times 2014, (July). Available from www.nytimes.com/2014/07/03/health/Vaccine-Costs-Soaring-Paying-Till-It-Hurts.html?_r=0 (accessed 31.12.14).
86. Pollack A. Pediatricians voice anger over costs of vaccines. The New York Times 2007, (March). Available from www.nytimes.com/2007/03/24/business/24vaccine.html?pagewanted=all (accessed 31.12.14).
87. Borland S. Now babies WILL get £20 meningitis jab: after year-long row over cost, NHS gives it the nod. Daily Mail 2015, (March). Available from www.dailymail.co.uk/news/article-3016859/All-British-babies-new-meningitis-B-vaccine-landmark-deal-months-negotiation-price-finally-resolved.html.
88. Christensen H., Trotter C.L., Hickman M., Edmunds W.J. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. Br Med J 2014, 349:g5725. PMCID: 4192138.
89. Miller M.A., Sutter R.W., Strebel P.M., Hadler S.C. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA 1996, 276:967-971.
90. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Broome C.V., et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993, 269:221-226.
91. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
92. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360:244-256.
93. Trotter C.L., Ramsay M.E., Kaczmarski E.B. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 2002, 5:220-225.